Table 1 Binding constants of nivolumab, pembrolizumab and prolgolimab towards PD-1 receptor, measured by SPR. PD-1 was immobilized on a chip, anti-PD-1 antibodies were in solution. ka—association constant. kd—dissociation constant. KD—equilibrium constant.
From: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
anti-PD-1 antibody | ka, (M × s)-1 | kd, s−1 | KD, M | |||
|---|---|---|---|---|---|---|
Mean | SD | Mean | SD | Mean | SD | |
Nivolumab | 2.66 × 106 | 7.25 × 105 | 1.83 × 10–5 | 4.66 × 10–06 | 6.89 × 10–12 | 3.16 × 10–13 |
Pembrolizumab | 3.73 × 106 | 2.05 × 105 | 1.75 × 10–5 | 4.60 × 10–06 | 4.70 × 10–12 | 6.20 × 10–13 |
Prolgolimab | 1.76 × 106 | 5.00 × 104 | 1.31 × 10–5 | 6.20 × 10–06 | 7.44 × 10–12 | 5.85 × 10–13 |
